Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.002185 USD | -12.60% | 0.00% | -74.71% |
2023 | Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
2023 | Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval | CI |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Royalty/Licensing, Net
90.2
%
| 0 | 83.9 % | 0 | 90.2 % | +11.35% |
Direct Sales - Plastic Surgeons, Gross
9.8
%
| 0 | 16.1 % | 0 | 9.8 % | -36.86% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +3.61% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 12-02-29 |
Don Calabria
COO | Chief Operating Officer | 53 | - |
Steven Barnes
IRC | Investor Relations Contact | - | 14-04-30 |
Corporate Officer/Principal | 68 | 22-02-28 | |
David Clark
SAM | Sales & Marketing | - | 19-05-02 |
Ira Weisberg
PRN | Corporate Officer/Principal | 75 | 22-11-29 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 12-02-29 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 600 | 0 | 0 | 77.47 % |
Stock B | 1 | 349,394,357 | 270,662,701 ( 77.47 %) | 0 | |
Stock C | 0 | 25,000 | 0 | 0 |
Company contact information
Endonovo Therapeutics, Inc.
6320 Canoga Avenue 15th Floor
91367, Woodland Hills
+800 489 4774
http://www.endonovo.comSector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
-74.71% | 873K | |
+9.15% | 105B | |
-1.08% | 104B | |
+5.79% | 22.94B | |
-11.55% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.91% | 16.96B | |
+7.55% | 14.16B | |
+40.04% | 12.63B |
- Stock Market
- Equities
- ENDV Stock
- Company Endonovo Therapeutics, Inc.